[The peptide analogue of neurotensin with antipsychotic and pro-cognitive effects: results of the pilot clinical trial].

What does this source report?

A 25-patient pilot reported symptom and cognitive changes in schizotypal disorder. Phenazepam was permitted and later added for insufficient response, limiting attribution to Dilept.

Population and setting

25 patients with schizotypal disorder

Evidence type

Uncontrolled human report

Preparation

See the original report; formulation details require verification.

Source language

English indexed abstract; original language: rus

Title provenance

Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.

What are the limitations?

• Small pilot; no randomized blinded comparator established in the abstract.
• Short observation and permitted/add-on phenazepam limit causal and safety conclusions.

Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.

Review depth: Abstract reviewed

Source access and review scope

Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.

Recorded source-check date: 2026-10-05. This date does not imply a completed systematic review.

Open original source or index record ↗

DOI: 10.17116/jnevro202012002122

Cite and trace this record

Original source: Neznamov GG, Bogdanova IO, Sunyakov TS, Dorofeeva OA, Kovalenok TV, Chepeluk AA. [The peptide analogue of neurotensin with antipsychotic and pro-cognitive effects: results of the pilot clinical trial]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2020.

Molekul research summary: https://molekul.io/research/rp-32307407. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.

Related compound profiles